ELI LILLY & (LLY) Company Report

Aktis Oncology raised $318 million in its initial public offering, bolstered by an anchor investment from Eli Lilly.
The collaboration between Eli Lilly and Aktis Oncology is valued at up to $1.2 billion, targeting development of alpha-emitting radiopharmaceuticals for solid tumors.
Aktis’s pipeline includes AKY-1189 (actinium-225–based targeting Nectin-4) and AKY-2519 (targeting B7-H3), following $346 million in prior private financing.
Vida Ventures co-led the Series A, is now Aktis’s second-largest shareholder, and has held board representation through Helen Kim since 2021.

1 day ago

Press Release

Lilly collaborates with Revvity to expand AI drug discovery models

LLY

New Projects/Investments

Revvity, Inc. (NYSE: RVTY) partners with Eli Lilly to make Lilly TuneLab predictive AI/ML models available through the Revvity Signals platform, broadening access to Lilly’s drug discovery tools.
The collaboration builds on Revvity’s Signals Xynthetica offering, establishing a scalable, federated framework to accelerate AI-enabled drug discovery.

1 day ago

Press Release

Eli Lilly collaborates with Chai Discovery to accelerate biologics discovery

LLY

New Projects/Investments

Eli Lilly partners with Chai Discovery to deploy its AI platform for biologics discovery, designing novel therapeutics across multiple targets.
Chai will build a purpose-built AI model, trained on proprietary Lilly data and tailored to Lilly’s discovery workflows.
The collaboration leverages Chai-2, a zero-shot antibody design platform achieving double-digit experimental hit rates, to reduce discovery timelines from months to weeks.
This partnership follows Chai’s Series B round in December 2025, which valued the company at $1.3 billion and brought total funding to $230 million.

1 day ago

Press Release

Lilly reports Phase 3b success for Zepbound plus Taltz in psoriatic arthritis

LLY

In the open-label Phase 3b TOGETHER-PsA trial, adults with active psoriatic arthritis and obesity/overweight receiving Zepbound + Taltz achieved a 31.7% rate of ≥50% PsA improvement plus ≥10% weight loss at 36 weeks versus 0.8% with Taltz alone.
The combination yielded an ACR50 rate of 33.5% versus 20.4% for Taltz monotherapy, a 64% relative increase in joint-response rates.
Adverse events were generally mild to moderate and aligned with known safety profiles (nausea, diarrhea, constipation, injection-site reactions) in the 271-participant study.
Lilly emphasized integrated PsA and cardiometabolic treatment for the ~65% of U.S. PsA patients who are obese or overweight.
Analysts noted Lilly’s strong financial position, trading near historical highs with robust revenue growth, high margins and a market cap of $967.7 billion.

2 days ago

Bloomberg

Lilly reports superior efficacy in Phase 3b PsA trial combining Taltz and Zepbound

LLY

At Week 36, concomitant Taltz and Zepbound met the primary endpoint: 31.7% of patients achieved ACR50 plus ≥10% weight reduction versus 0.8% on Taltz alone (p<.001).
In a key secondary endpoint, the combination delivered a 64% relative increase in ACR50 response (33.5% vs. 20.4%, p<.05), demonstrating improved PsA activity with added weight reduction therapy.
The TOGETHER-PsA trial randomized 271 adults (mean BMI 37.6 kg/m²) with active PsA and obesity/overweight; adverse events were mostly mild to moderate and aligned with known safety profiles.

2 days ago

Press Release

Ray Therapeutics appoints Scott Braunstein as Chairman of the Board

LLY

Board Change

New Projects/Investments

Ray Therapeutics appoints Scott Braunstein, M.D. as Chairman of the Board, drawing on his 30+ years of biopharma and investment experience.
Braunstein’s prior roles include Chairman & CEO of Marinus Pharmaceuticals, SVP & COO at Pacira Pharmaceuticals, and Managing Director at J.P. Morgan Asset Management, plus board seats at multiple biotech firms.
His leadership is expected to accelerate the company’s optogenetic gene therapy programs RTx-015 for retinitis pigmentosa and RTx-021 for Stargardt disease through Phase 1 trials.

3 days ago

Press Release

Eli Lilly to acquire Ventyx Biosciences

LLY

M&A

Lilly enters a definitive agreement to acquire Ventyx for $14.00 per share in an all-cash transaction valued at $1.2 billion.
The purchase price represents a 62% premium to Ventyx’s 30-day volume-weighted average price ended January 5, 2026.
The deal, approved by both boards, is expected to close in the first half of 2026, subject to Ventyx stockholder and regulatory approvals.
The acquisition enhances Lilly’s inflammation-focused pipeline by adding Ventyx’s clinical-stage NLRP3 inhibitors targeting cardiometabolic, neurodegenerative and inflammatory diseases.

3 days ago

Press Release

Lilly announces strategic oncology collaboration with InduPro

LLY

New Projects/Investments

Eli Lilly and InduPro entered a global strategic collaboration to develop first-in-class bispecific/multispecific oncology therapeutics across three targets with a total deal value of up to $950 million.
Lilly will make an equity investment in InduPro as part of the agreement.
InduPro will apply its AI/ML-enabled membrane interactomics (MInt) platform to identify Tumor Associated Proximity Antigens paired with tumor-associated antigens for bispecific ADCs and multispecific T-cell engagers.

3 days ago

Press Release

Volastra expands KIF18A inhibitor program and names new CMO

LLY

Management Change

New Projects/Investments

Volastra is broadening its lead KIF18Ai program into lung, head and neck cancers following positive monotherapy expansion data in platinum-resistant ovarian cancer and early biomarker correlations.
The company will launch its first combination trial in Q1 2026, testing KIF18Ai with standard chemotherapies in ovarian, lung, and breast cancers, with safety readouts due in Q2 and efficacy data in H2 2026.
Volastra anticipates an FDA End-of-Phase meeting in H2 2026 to discuss potential registrational trials after securing Fast Track designation for platinum-resistant ovarian cancer.
Timothy Bowler, M.D., Ph.D., has been appointed Chief Medical Officer to lead clinical strategy and oversee the program’s expansion.

4 days ago

Press Release

Eli Lilly nears $1B Ventyx acquisition

LLY

M&A

Eli Lilly is in advanced talks to acquire Ventyx Biosciences for over $1 billion, with a deal potentially announced imminently.
Ventyx shares surged 28.5% to $10.05 in regular trading and climbed 62.6% to $16.34 in after‐hours.
Eli Lilly’s financials include $59.42 billion in revenue, a 30.99% net margin, a 45.16% operating margin, and a $951.91 billion market cap, supported by an Altman Z-Score of 7.83.
Ventyx is a pre‐revenue, clinical‐stage biotech (EPS ≈ −1.5) with a market cap near $717.15 million and strong liquidity (current and quick ratios of 17.86).